Oncolytics Biotech Company Profile (TSE:ONC)

About Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech logoOncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: C$62.14 million
  • Outstanding Shares: 121,836,000
Average Prices:
  • 50 Day Moving Avg: C$0.51
  • 200 Day Moving Avg: C$0.56
  • 52 Week Range: C$0.19 - C$1.13
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: C$0.06 per share
  • Price / Book: 8.50
Profitability:
  • EBIDTA: ($13,310,000.00)
  • Return on Equity: -157.09%
  • Return on Assets: -111.18%
Misc:
  • Average Volume: 366,338 shs.
  • Short Ratio: 1.33
 
Frequently Asked Questions for Oncolytics Biotech (TSE:ONC)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ONC."

Where is Oncolytics Biotech's stock going? Where will Oncolytics Biotech's stock price be in 2017?

2 brokerages have issued 12-month target prices for Oncolytics Biotech's shares. Their predictions range from C$1.50 to C$1.50. On average, they expect Oncolytics Biotech's stock price to reach C$1.50 in the next year. View Analyst Ratings for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:

  • Wayne F. Pisano, Chairman of the Board
  • Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
  • Kirk J. Look, Chief Financial Officer
  • George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
  • Mary Ann Dillahunty J.D., Vice President - Intellectual Property
  • Andres A. Gutierrez M.D., PhD., Chief Medical Officer
  • Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer
  • Angela Frances Holtham, Director
  • Edwin Levy Ph.D., Director
  • J. Mark Lievonen, Director

How do I buy Oncolytics Biotech stock?

Shares of Oncolytics Biotech and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of Oncolytics Biotech stock can currently be purchased for approximately C$0.51.


MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Oncolytics Biotech (TSE:ONC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: C$1.50

Analysts' Ratings History for Oncolytics Biotech (TSE:ONC)
Show:
DateFirmActionRatingPrice TargetDetails
4/13/2017BMO Capital MarketsBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
4/13/2017Royal Bank Of CanadaBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
8/7/2015Canaccord GenuityLower Price TargetBuyC$2.50 -> C$1.75View Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Oncolytics Biotech (TSE:ONC)
Earnings by Quarter for Oncolytics Biotech (TSE:ONC)
Earnings History by Quarter for Oncolytics Biotech (TSE ONC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2 14($0.07)($0.05)ViewN/AView Earnings Details
11/7/2013Q3 13($0.07)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Oncolytics Biotech (TSE:ONC)
Current Year EPS Consensus Estimate: $-0.11 EPS

Dividends

Dividend History for Oncolytics Biotech (TSE:ONC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oncolytics Biotech (TSE:ONC)
Insider Trades by Quarter for Oncolytics Biotech (TSE:ONC)
Insider Trades by Quarter for Oncolytics Biotech (TSE:ONC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2015Angela Frances HolthamDirectorBuy5,000C$0.89C$4,450.00
5/12/2015Wayne PisanoDirectorBuy20,000C$0.76C$15,150.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Oncolytics Biotech (TSE:ONC)
Latest Headlines for Oncolytics Biotech (TSE:ONC)
Source:
DateHeadline
reuters.com logoBRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM
finance.yahoo.com logoOncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM
finance.yahoo.com logoOncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM
prnewswire.com logoOncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM
finance.yahoo.com logoOncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
finance.yahoo.com - June 30 at 2:53 AM
prnewswire.com logoOncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM
finance.yahoo.com logoToday's Research Reports on Oncolytics Biotech, Spectral Medical, CRH Medical and ESSA Pharma
finance.yahoo.com - June 26 at 8:31 AM
finance.yahoo.com logoOncolytics Biotech® Announces Closing of Public Offering of Units
finance.yahoo.com - June 1 at 7:52 PM
finance.yahoo.com logoIIROC Trade Resumption - ONC.WT
finance.yahoo.com - June 1 at 7:52 PM
finance.yahoo.com logoIIROC Trade Halt - Oncolytics Biotech Inc. Common share purchase warrants
finance.yahoo.com - June 1 at 8:46 AM
finance.yahoo.com logoIIROC Trading Halt - ONC.WT
finance.yahoo.com - June 1 at 8:46 AM
prnewswire.com logoOncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM
marketwatch.com logoOncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM
reuters.com logoBRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM
finance.yahoo.com logoIIROC Trade Halt - Oncolytics Biotech Inc.
finance.yahoo.com - May 24 at 10:17 AM
finance.yahoo.com logoIIROC Trading Halt - ONC
finance.yahoo.com - May 24 at 10:17 AM
finance.yahoo.com logoOncolytics Biotech® Announces Proposed Public Offering
finance.yahoo.com - May 23 at 6:31 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
finance.yahoo.com - May 23 at 10:04 AM
finance.yahoo.com logoOncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
finance.yahoo.com - May 17 at 6:58 PM
baystreet.ca logoFDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM
reuters.com logoBRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
finance.yahoo.com - May 8 at 12:09 PM
prnewswire.com logoOncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM
prnewswire.com logoOncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM
marketbeat.com logoOncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders - Yahoo Finance
finance.yahoo.com - April 29 at 7:28 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces Details of 2017 Annual Meeting of Shareholders
finance.yahoo.com - April 27 at 10:15 AM
finance.yahoo.com logoONCYF: REOLYSIN Clinical Development Plan - Yahoo Finance
finance.yahoo.com - April 18 at 6:23 PM
finance.yahoo.com logoONCYF: REOLYSIN Clinical Development Plan
finance.yahoo.com - April 17 at 6:12 PM
seekingalpha.com logoOncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM
americanbankingnews.com logoOncolytics Biotech Inc. (ONC) Price Target Raised to C$1.50
www.americanbankingnews.com - April 13 at 4:04 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan
finance.yahoo.com - April 12 at 11:54 AM
finance.yahoo.com logoOncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer
finance.yahoo.com - April 7 at 11:43 AM
americanbankingnews.com logoOncolytics Biotech Inc. (ONC) PT Set at C$1.00 by Royal Bank of Canada
www.americanbankingnews.com - April 3 at 4:27 PM
finance.yahoo.com logoIIROC Trade Resumption - ONC
finance.yahoo.com - April 3 at 9:30 AM
finance.yahoo.com logoOncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival …
finance.yahoo.com - March 31 at 7:08 PM
finance.yahoo.com logoIIROC Trading Halt - ONC (all issues)
finance.yahoo.com - March 31 at 7:07 PM
globenewswire.com logoBiopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM
finance.yahoo.com logoONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
finance.yahoo.com - March 21 at 6:53 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma
finance.yahoo.com - March 16 at 8:47 AM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces 2016 Year-End Results
finance.yahoo.com - March 10 at 9:16 AM
reuters.com logoBRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM
finance.yahoo.com logoOncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting
finance.yahoo.com - March 2 at 8:38 AM
globenewswire.com logoGlobal Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM
finance.yahoo.com logoBristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - Yahoo Finance
finance.yahoo.com - January 29 at 12:10 AM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks Oncolytics Biotech, ProMetic Life Sciences, Resverlogix, and Helius Medical Technologies
finance.yahoo.com - January 27 at 12:12 AM
prnewswire.com logoOncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM
reuters.com logoBRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM
finance.yahoo.com logoOncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO
finance.yahoo.com - January 19 at 11:41 PM
globenewswire.com logoTargovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM

Social

Chart

Oncolytics Biotech (ONC) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff